The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation

Atherosclerosis

Volumn 228, Issue 2, 2013, Pages 295-305

  Krishna, Smriti Murali ^a   Dear, Anthony ^b   Craig, Jeffrey M ^c   Norman, Paul E ^d   Golledge, Jonathan ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Abdominal aortic aneurysm; DNA methylation; Epigenetics; Hcy memory effect; Homocysteine

Indexed keywords

HOMOCYSTEINE; METHIONINE;

ABDOMINAL AORTA ANEURYSM; DISEASE COURSE; DNA METHYLATION; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; EPIGENETICS; GENE TARGETING; HISTONE MODIFICATION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; TARGET ORGAN;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; HISTONES; HOMOCYSTEINE; HUMANS; PHENOTYPE; PROGNOSIS; RISK FACTORS; UP-REGULATION;

EID: 84878107564     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.019     Document Type: Review

References (161)

1. Fuster V., Voute J. MDGs: chronic diseases are not on the agenda. Lancet 2005, 366(9496):1512-1514.
2. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367(9524):1747-1757.
3. Paradis G., Chiolero A. The cardiovascular and chronic diseases epidemic in low- and middle-income countries a global health challenge. J Am Coll Cardiol 2011, 57(17):1775-1777.
4. Smith S.C., Amsterdam E., Balady G.J., et al. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: tests for silent and inducible ischemia: Writing Group II. Circulation 2000, 101(1):E12-E16.
5. Moxon J.V., Parr A., Emeto T.I., Walker P., Norman P.E., Golledge J. Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects. Curr Probl Cardiol 2010, 35(10):512-548.
6. Lindsay M.E., Dietz H.C. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 2011, 473(7347):308-316.
7. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26(12):2605-2613.
8. Lederle F.A., Wilson S.E., Johnson G.R., et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002, 346(19):1437-1444.
9. Wang Y.X., Martin-McNulty B., da Cunha V., et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 2005, 111(17):2219-2226.
10. Yoshimura K., Aoki H., Ikeda Y., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005, 11(12):1330-1338.
11. Lindeman J.H., Abdul-Hussien H., van Bockel J.H., Wolterbeek R., Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009 Apr 28, 119(16):2209-2216.
12. Kajimoto K., Miyauchi K., Kasai T., et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009 Oct, 206(2):505-511.
13. Liu O., Jia L., Liu X., et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One 2012, 7(12):e51707.
14. Krishna S.M., Dear A.E., Norman P.E., Golledge J. Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm. Atherosclerosis 2010, 212(1):16-29.
15. Giles W.H., Kittner S.J., Anda R.F., Croft J.B., Casper M.L. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke 1995, 26(7):1166-1170.
16. Brattstrom L., Wilcken D.E. Homocysteine and cardiovascular disease: cause or effect?. Am J Clin Nutr 2000, 72(2):315-323.
17. Joseph J., Handy D.E., Loscalzo J. Quo vadis: whither homocysteine research?. Cardiovasc Toxicol 2009, 9(2):53-63.
18. Becker A., Kostense P.J., Bos G., et al. Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Intern Med 2003, 253(3):293-300.
19. Ambrosi P., Rolland P.H., Bodard H., et al. Effects of folate supplementation in hyperhomocysteinemic pigs. J Am Coll Cardiol 1999, 34(1):274-279.
20. Hofmann M.A., Lalla E., Lu Y., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001, 107(6):675-683.
21. Zhou J., Moller J., Danielsen C.C., et al. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21(9):1470-1476.
22. Fujimoto S., Togane Y., Matsuzaki C., et al. Effects of long-term administration of methionine on vascular endothelium in rabbits. Nutr Metab Cardiovasc Dis 2003, 13(1):20-27.
23. Matthias D., Becker C.H., Riezler R., Kindling P.H. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 1996, 122(2):201-216.
24. Zhang R., Ma J., Xia M., Zhu H., Ling W. Mild hyperhomocysteinemia induced by feeding rats diets rich in methionine or deficient in folate promotes early atherosclerotic inflammatory processes. J Nutr 2004, 134(4):825-830.
25. Zulli A., Hare D.L., Buxton B.F., Black M.J. High dietary methionine plus cholesterol exacerbates atherosclerosis formation in the left main coronary artery of rabbits. Atherosclerosis 2004, 176(1):83-89.
26. Chang P.Y., Lu S.C., Lee C.M., et al. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res 2008, 102(8):933-941.
27. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325(7374):1202.
28. Den Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005, 3(2):292-299.
29. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002 Oct 23-30, 288(16):2015-2022. Homocysteine Studies Collaboration.
30. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268(7):877-881.
31. Faraci F.M., Lentz S.R. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 2004, 35(2):345-347.
32. Ungvari Z., Csiszar A., Edwards J.G., et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003, 23(3):418-424.
33. Eberhardt R.T., Forgione M.A., Cap A., et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000, 106(4):483-491.
34. Lentz S.R., Erger R.A., Dayal S., et al. Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. Am J Physiol Heart Circ Physiol 2000, 279(3):H970-H975.
35. Riba R., Nicolaou A., Troxler M., Homer-Vaniasinkam S., Naseem K.M. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004, 175(1):69-75.
36. Schroecksnadel K., Frick B., Winkler C., Leblhuber F., Wirleitner B., Fuchs D. Hyperhomocysteinemia and immune activation. Clin Chem Lab Med 2003, 41(11):1438-1443.
37. Yideng J., Jianzhong Z., Ying H., et al. Homocysteine-mediated expression of SAHH, DNMTs, MBD2, and DNA hypomethylation potential pathogenic mechanism in VSMCs. DNA Cell Biol 2007, 26(8):603-611.
38. Majors A., Ehrhart L.A., Pezacka E.H. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17(10):2074-2081.
39. Chen N.C., Yang F., Capecci L.M., et al. Regulation of homocysteine metabolism and methylation in human and mouse tissues. FASEB J 2010, 24(8):2804-2817.
40. Zhang D., Jiang X., Fang P., et al. Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation 2009, 120(19):1893-1902.
41. Van Campenhout A., Moran C.S., Parr A., et al. Role of homocysteine in aortic calcification and osteogenic cell differentiation. Atherosclerosis 2009, 202(2):557-566.
42. Wiernicki I., Millo B., Safranow K., Gorecka-Szyld B., Gutowski P. MMP-9, homocysteine and CRP circulating levels are associated with intraluminal thrombus thickness of abdominal aortic aneurysms: new implication of the old biomarkers. Dis Markers 2011, 31(2):67-74.
43. Xu Y., Tian Y., Wei H.J., Dong J.F., Zhang J.N. Methionine diet-induced hyperhomocysteinemia accelerates cerebral aneurysm formation in rats. Neurosci Lett 2011, 494(2):139-144.
44. Giusti B., Porciani M.C., Brunelli T., et al. Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur Heart J 2003, 24(22):2038-2045.
45. Dayal S., Bottiglieri T., Arning E., et al. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res 2001, 88(11):1203-1209.
46. Lee M.E., Wang H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med 1999, 9(1-2):49-54.
47. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996, 98(1):5-7.
48. Nishio E., Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol 1997, 122(2):269-274.
49. Chambers J.C., McGregor A., Jean-Marie J., Kooner J.S. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998, 351(9095):36-37.
50. Zhou J., Austin R.C. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. Biofactors 2009, 35(2):120-129.
51. Zhang X., Li H., Jin H., Ebin Z., Brodsky S., Goligorsky M.S. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Ren Physiol 2000, 279(4):F671-F678.
52. Upchurch G.R., Welch G.N., Fabian A.J., et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997, 272(27):17012-17017.
53. Hamelahti P., Jarvinen O., Sisto T., et al. Methylenetetrahydrofolate reductase gene C677T mutation is related to the defects in the internal elastic lamina of the artery wall. Eur J Clin Invest 2002, 32(12):869-873.
54. Moat S.J., Lang D., McDowell I.F., et al. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 2004, 15(2):64-79.
55. Jourdheuil-Rahmani D., Rolland P.H., Rosset E., Branchereau A., Garcon D. Homocysteine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors. Cardiovasc Res 1997, 34(3):597-602.
56. Chaussalet M., Lamy E., Foucault-Bertaud A., et al. Homocysteine modulates the proteolytic potential of human vascular endothelial cells. Biochem Biophys Res Commun 2004, 316:170-176.
57. Charpiot P., Bescond A., Augier T., et al. Hyperhomocysteinemia induces elastolysis in minipig arteries: structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Matrix Biol 1998, 17(8-9):559-574.
58. Neves M.F., Endemann D., Amiri F., et al. Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. J Hypertens 2004, 22(5):959-966.
59. Bortolotto L.A., Safar M.E., Billaud E., et al. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 1999, 34(4 Pt 2):837-842.
60. Bescond A., Augier T., Chareyre C., Garcon D., Hornebeck W., Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999, 263(2):498-503.
61. Ke X.D., Foucault-Bertaud A., Genovesio C., Dignat-George F., Lamy E., Charpiot P. Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism. Mol Cell Biochem 2010, 335(1-2):203-210.
62. Tsarouhas K., Tsitsimpikou C., Apostolakis S., et al. Homocysteine and metalloprotease-3 and -9 in patients with ascending aorta aneurysms. Thromb Res 2011 Nov, 128(5):e95-e99.
63. Lentz S.R., Sadler J.E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991, 88(6):1906-1914.
64. Lentz S.R., Sadler J.E. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993, 81(3):683-689.
65. Austin R.C., Lentz S.R., Werstuck G.H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004, 11(Suppl. 1):S56-S64.
66. Kaufman R.J. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002, 110(10):1389-1398.
67. Dickhout J.G., Sood S.K., Austin R.C. Role of endoplasmic reticulum calcium disequilibria in the mechanism of homocysteine-induced ER stress. Antioxid Redox Signal 2007, 9(11):1863-1873.
68. Jia F., Wu C., Chen Z., Lu G. Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase. Cardiovasc Ther 2012, 30(6):317-325.
69. Liu Z., Luo H., Zhang L., et al. Hyperhomocysteinemia exaggerates adventitial inflammation and angiotensin II-induced abdominal aortic aneurysm in mice. Circ Res 2012 Oct 26, 111(10):1261-1273.
70. Zhang D., Fang P., Jiang X., et al. Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res 2012 Jun 22, 111(1):37-49.
71. Zhang Q., Zeng X., Guo J., Wang X. Oxidant stress mechanism of homocysteine potentiating Con A-induced proliferation in murine splenic T lymphocytes. Cardiovasc Res 2002, 53(4):1035-1042.
72. Mei W., Rong Y., Jinming L., Yongjun L., Hui Z. Effect of homocysteine interventions on the risk of cardio-cerebrovascular events: a meta-analysis of randomised controlled trials. Int J Clin Pract 2010 Jan, 64(2):208-215.
73. Lentz S.R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005, 3(8):1646-1654.
74. Ueland P.M., Refsum H., Beresford S.A., Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000, 72(2):324-332.
75. Brunelli T., Prisco D., Fedi S., et al. High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg 2000, 32(3):531-536.
76. Caldwell S., Burns P., Haggart P., Bradbury A., Mosquera D. Association between hyperhomocysteinaemia and abdominal aortic aneurysm. Br J Surg 2001, 88:609.
77. Spark J., Laws P., Fitridge R. The incidence of hyperhomocysteinaemia in vascular patients. Eur J Vasc Endovasc Surg 2003, 26:558-561.
78. Warsi A., Davies B., Morris-Stiff G., Hullin D., Lewis M. Abdominal aortic aneurysm and its correlation to plasma homocysteine, and vitamins. Eur J Endovasc Surg 2004, 27:75-79.
79. Peeters A.C., van Landeghem B.A., Graafsma S.J., et al. Low vitamin B6, and not plasma homocysteine concentration, as risk factor for abdominal aortic aneurysm: a retrospective case-control study. J Vasc Surg 2007, 45(4):701-705.
80. Sofi F., Marcucci R., Giusti B., et al. High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb Haemost 2005, 94(5):1094-1098.
81. Moroz P., Le M.T., Norman P.E. Homocysteine and abdominal aortic aneurysms. ANZ J Surg 2007, 77(5):329-332.
82. Halazun K.J., Bofkin K.A., Asthana S., Evans C., Henderson M., Spark J.I. Hyperhomocysteinaemia is associated with the rate of abdominal aortic aneurysm expansion. Eur J Vasc Endovasc Surg 2007, 33(4):391-394.
83. Muskiet F.A. The importance of (early) folate status to primary and secondary coronary artery disease prevention. Reprod Toxicol 2005, 20(3):403-410.
84. Blom H.J. Homocysteine and cholesterol, basic and clinical interactions in Hcy and vascular disease 2000, 335-348. Kluwer Academic Publishers, Dordrecht, The Netherlands. K. Robinson (Ed.).
85. Giusti B., Saracini C., Bolli P., et al. Abbate R genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm. J Med Genet 2008 Nov, 45(11):721-730.
86. Strauss E., Waliszewski K., Gabriel M., Zapalski S., Pawlak A.L. Increased risk of the abdominal aortic aneurysm in carriers of the MTHFR 677T allele. J Appl Genet 2003, 44(1):85-93.
87. Chen Z., Karaplis A., Ackerman S.L., et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001 Mar, 10(5):433-443.
88. Harrison S.C., Holmes M.V., Agu O., Humphries S.E. Genome wide association studies of abdominal aortic aneurysms-biological insights and potential translation applications. Atherosclerosis 2011, 217(1):47-56.
89. Jones G.T., Harris E.L., Phillips L., van Rij A.M. The methylenetetrahydrofolate reductase C677T polymorphism does not associate with susceptibility to abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2005, 30(2):137-142.
90. Ferrara F., Novo S., Grimaudo S., et al. Methylenetetrahydrofolate reductase mutation in subjects with abdominal aortic aneurysm divided by age. Clin Hemorheol Microcirc 2006, 34:421-426.
91. Sharma P., Senthilkumar R.D., Brahmachari V., et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Review Lipids Health Dis 2006 Jan 23, 5(1).
92. Dragani A., Falco A., Santilli F., et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C>T polymorphism. Thromb Haemost 2012 Sep, 108(3):533-542.
93. Malinowska J., Olas B. Homocysteine and its thiolactone-mediated modification of fibrinogen affect blood platelet adhesion. Platelets 2012, 23(5):409-412.
94. Rasmussen K., Møller J. Total homocysteine measurement in clinical practice. Ann Clin Biochem 2000, 37(Pt 5):627-648.
95. Bellamy M.F., McDowell I.F., Ramsey M.W., et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998, 98:1848-1852.
96. Dawson H., Collins G., Pyle R., Deep-Dixit V., Taub D.D. The immunoregulatory effects of homocysteine and its intermediates on t-lymphocyte function. Mech Ageing Dev 2004, 125:107-110.
97. Ungvari Z., Pacher P., Rischak K., Szollar L., Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1999, 19:1899-1904.
98. Hershfield M.S., Kredich N.M., Koller C.A., et al. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. Cancer Res 1983, 43(7):3451-3458.
99. Caudill M.A., Wang J.C., Melnyk S., et al. Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. J Nutr 2001, 131(11):2811-2818.
100. Capdevila A., Decha-Umphai W., Song K.H., Borchardt R.T., Wagner C. Pancreatic exocrine secretion is blocked by inhibitors of methylation. Arch Biochem Biophys 1997, 345(1):47-55.
101. Castro R., Rivera I., Martins C., et al. Intracellular S-adenosylhomocysteine increased levels are associated with DNA hypomethylation in HUVEC. J Mol Med (Berl) 2005, 83(10):831-836.
102. Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 2011, 32(1):82-88.
103. Kerins D.M., Koury M.J., Capdevila A., Rana S., Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. Am J Clin Nutr 2001, 74(6):723-729.
104. Wagner C., Koury M.J. S-Adenosylhomocysteine: a better indicator of vascular disease than homocysteine?. Am J Clin Nutr 2007, 86(6):1581-1585.
105. Ingrosso D., Cimmino A., Perna A.F., et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003, 361(9370):1693-1699.
106. Yi P., Melnyk S., Pogribna M., Pogribny I.P., Hine R.J., James S.J. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000, 275(38):29318-29323.
107. Ikegami K., Ohgane J., Tanaka S., Yagi S., Shiota K. Interplay between DNA methylation, histone modification and chromatin remodelling in stem cells and during development. Int J Dev Biol 2009, 53(2-3):203-214.
108. James S.J., Melnyk S., Pogribna M., Pogribny I.P., Caudill M.A. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002, 132(8 Suppl.):2361S-2366S.
109. Bestor T.H. The DNA methyltransferases of mammals. Hum Mol Genet 2000, 9(16):2395-2402.
110. Perna A.F., Ingrosso D., Lombardi C., et al. Possible mechanisms of homocysteine toxicity. Kidney Int Suppl 2003, 84:S137-S140.
111. Williams K.T., Garrow T.A., Schalinske K.L. Type I diabetes leads to tissue-specific DNA hypomethylation in male rats. J Nutr 2008, 138(11):2064-2069.
112. Zaina S., Lindholm M.W., Lund G. Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia?. J Nutr 2005, 135(1):5-8.
113. Pascale R.M., Simile M.M., De Miglio M.R., Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 2002, 27(3):193-198.
114. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol Sci 2007, 100(1):7-23.
115. Jamaluddin M.D., Chen I., Yang F., et al. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 2007, 110(10):3648-3655.
116. Castro R., Rivera I., Struys E.A., et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 2003, 49(8):1292-1296.
117. Perna A.F., Ingrosso D., de Santo N.G., Galletti P., Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995, 47(1):247-253.
118. Perna A.F., Ingrosso D., de Santo N.G., Galletti P., Brunone M., Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997, 8(12):1899-1905.
119. Perna A.F., Ingrosso D., Zappia V., Galletti P., Capasso G., de Santo N.G. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 1993, 91(6):2497-2503.
120. Jamaluddin M.S., Yang X., Wang H. Hyperhomocysteinemia, DNA methylation and vascular disease. Clin Chem Lab Med 2007, 45(12):1660-1666.
121. Wang H., Yoshizumi M., Lai K., et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997, 272(40):25380-25385.
122. Sharma P., Kumar J., Garg G., et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol 2008, 27(7):357-365.
123. Fryer A.A., Emes R.D., Ismail K.M., et al. Quantitative, high-resolution epigenetic profiling of CpG loci identifies associations with cord blood plasma homocysteine and birth weight in humans. Epigenetics 2011, 6(1):86-94.
124. Dong C., Yoon W., Goldschmidt-Clermont P.J. DNA methylation and atherosclerosis. J Nutr 2002, 132(8 Suppl.):2406S-2409S.
125. Lund G., Andersson L., Lauria M., et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 2004, 279(28):29147-29154.
126. Liu C., Wang Q., Guo H., et al. Plasma S-adenosylhomocysteine is a better biomarker of atherosclerosis than homocysteine in apolipoprotein E-deficient mice fed high dietary methionine. J Nutr 2008, 138(2):311-315.
127. Hiltunen M.O., Turunen M.P., Hakkinen T.P., et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002, 7(1):5-11.
128. Li Y., Liu Y., Strickland F.M., Richardson B. Age-dependent decreases in DNA methyltransferase levels and low transmethylation micronutrient levels synergize to promote overexpression of genes implicated in autoimmunity and acute coronary syndromes. Exp Gerontol 2010, 45(4):312-322.
129. Zhang J.G., Liu J.X., Li Z.H., Wang L.Z., Jiang Y.D., Wang S.R. Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. Chin Med J (Engl) 2007, 120(23):2132-2137.
130. Bleich S., Lenz B., Ziegenbein M., et al. Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence. Alcohol Clin Exp Res 2006, 30(4):587-591.
131. Lenz B., Bleich S., Beutler S., et al. Homocysteine regulates expression of Herp by DNA methylation involving the AARE and CREB binding sites. Exp Cell Res 2006, 312(20):4049-4055.
132. Huang Y., Peng K., Su J., Xu Y., Wang S. Different effects of homocysteine and oxidized low density lipoprotein on methylation status in the promoter region of the estrogen receptor alpha gene. Acta Biochim Biophys Sin (Shanghai) 2007, 39(1):19-26.
133. Kim J., Kim J.Y., Song K.S., et al. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta 2007, 1772(1):72-80.
134. Yi-Deng J., Tao S., Hui-Ping Z., et al. DNA methylation induced by homocysteine in human monocytes. DNA Cell Biol 2007, 26(10):737-744.
135. Yideng J., Zhihong L., Jiantuan X., Jun C., Guizhong L., Shuren W. Homocysteine-mediated PPARalpha, gamma DNA methylation and its potential pathogenic mechanism in monocytes. DNA Cell Biol 2008, 27(3):143-150.
136. Li L., Xie J., Zhang M., Wang S. Homocysteine harasses the imprinting expression of IGF2 and H19 by demethylation of differentially methylated region between IGF2/H19 genes. Acta Biochim Biophys Sin (Shanghai) 2009, 41(6):464-471.
137. Devlin A.M., Bottiglieri T., Domann F.E., Lentz S.R. Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. J Biol Chem 2005, 280(27):25506-25511.
138. Jiang Y., Zhang J., Xiong J., Cao J., Li G., Wang S. Ligands of peroxisome proliferator-activated receptor inhibit homocysteine-induced DNA methylation of inducible nitric oxide synthase gene. Acta Biochim Biophys Sin (Shanghai) 2007, 39(5):366-376.
139. Bonaldi T., Imhof A., Regula J.T. A combination of different mass spectroscopic techniques for the analysis of dynamic changes of histone modifications. Proteomics 2004, 4(5):1382-1396.
140. Zhang K., Tang H. Analysis of core histones by liquid chromatography-mass spectrometry and peptide mapping. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 783(1):173-179.
141. Jiang Y., Jiang J., Xiong J., et al. Homocysteine-induced extracellular superoxide dismutase and its epigenetic mechanisms in monocytes. J Exp Biol 2008, 211(6):911-920.
142. Choi J.H., Nam K.H., Kim J., et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25(11):2404-2409.
143. Shane B., Stokstad E.L. Vitamin B12-folate interrelationships. Annu Rev Nutr 1985, 5:115-141.
144. Friso S., Choi S.W. Gene-nutrient interactions and DNA methylation. J Nutr 2002, 132(8 Suppl.):2382S-2387S.
145. Kruman, Culmsee C., Chan S.L., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000, 20(18):6920-6926.
146. Choi S.W., Mason J.B. Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 2002, 132(8 Suppl.):2413S-2418S.
147. Piyathilake C.J., Celedonio J.E., Macaluso M., Bell W.C., Azrad M., Grizzle W.E. Mandatory fortification with folic acid in the United States is associated with increased expression of DNA methyltransferase-1 in the cervix. Nutrition 2008, 24(1):94-99.
148. Sauer J., Mason J.B., Choi S.W. Too much folate: a risk factor for cancer and cardiovascular disease?. Curr Opin Clin Nutr Metab Care 2009, 12(1):30-36.
149. Clapin H.F., Fritschi L., Iacopetta B., Heyworth J.S. Dietary and supplemental folate and the risk of left- and right-sided colorectal cancer. Nutr Cancer 2012, 64(7):937-945.
150. Williams E.A. Folate, colorectal cancer and the involvement of DNA methylation. Proc Nutr Soc 2012, 71(4):592-597.
151. Yang Q., Botto L.D., Erickson J.D., et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006, 113(10):1335-1343.
152. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006, 354(15):1567-1577.
153. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006, 354(15):1578-1588.
154. Hoffer L.J. Testing the homocysteine hypothesis in end-stage renal disease: problems and a possible solution. Kidney Int 2006, 69(9):1507-1510.
155. Saposnik G., Ray J.G., Sheridan P., McQueen M., Lonn E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009, 40(4):1365-1372.
156. Hodis H.N., Mack W.J., Dustin L., et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke 2009, 40(3):730-736.
157. Maron B.A., Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 2009, 60:39-54.
158. Mager A., Orvin K., Koren-Morag N., et al. Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease. Am J Cardiol 2009, 104(6):745-749.
159. Bazzano L.A. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci 2009, 338(1):48-49.
160. Song Y., Cook N.R., Albert C.M., Van Denburgh M., Manson J.E. Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009, 58(8):1921-1928.
161. Ingrosso D., Perna A.F. Epigenetics in hyperhomocysteinemic states. A special focus on uremia. Biochim Biophys Acta 2009, 1790(9):892-899.